biostudies-literatureEjo MMedical Research Council839-845https://www.ebi.ac.uk/biostudies/studies/S-EPMC7614701biostudies-literatureUnknown25(10)<b>OBJECTIVES:</b> To assess the performance of the GenoType MTBDR<i>sl</i> v1, a line-probe assay (LPA), to exclude baseline resistance to fluoroquinolones (FQs) and second-line injectables (SLIs) in the Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB 1 (STREAM 1) trial.<b>METHODS:</b> Direct sputum MTBDR<i>sl</i> results in the site laboratories were compared to indirect phenotypic drug susceptibility testing (pDST) results in the central laboratory, with DNA sequencing as a reference standard.<b>RESULTS:</b> Of 413 multidrug-resistant TB (MDR-TB) patients tested using MTBDR<i>sl</i> and pDST, 389 (94.2%) were FQ-susceptible and 7 (1.7%) FQ-resistant, while 17 (4.1%) had an inconclusive MTBDR<i>sl</i> result. For SLI, 372 (90.1%) were susceptible, 5 (1.2%) The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung DiseaseEffectiveness of GenoType MTBDR<i>sl</i> in excluding TB drug resistance in a clinical trial.PMC7614701MC_EX_MR/J012513/1MC_UU_00004/04MR/J012513/1MC_UU_12023/26Diro EMeredith SAhmed SEjo MKokebu DKeysers JTumenbayar ODuckworth LNgubane NConradie FMulders WDe Rijk PHang PTEnduwamahoro EDat PTMebrahtu TMoodliar RVan Deun ATsogt BTorrea Gde Jong BCHa DTMNunn ADalai DRigouts LTeferi MfalseEffectiveness of GenoType MTBDR<i>sl</i> in excluding TB drug resistance in a clinical trial.<b>OBJECTIVES:</b> To assess the performance of the GenoType MTBDR<i>sl</i> v1, a line-probe assay (LPA), to exclude baseline resistance to fluoroquinolones (FQs) and second-line injectables (SLIs) in the Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB 1 (STREAM 1) trial.<b>METHODS:</b> Direct sputum MTBDR<i>sl</i> results in the site laboratories were compared to indirect phenotypic drug susceptibility testing (pDST) results in the central laboratory, with DNA sequencing as a reference standard.<b>RESULTS:</b> Of 413 multidrug-resistant TB (MDR-TB) patients tested using MTBDR<i>sl</i> and pDST, 389 (94.2%) were FQ-susceptible and 7 (1.7%) FQ-resistant, while 17 (4.1%) had an inconclusive MTBDR<i>sl</i> result. For SLI, 372 (90.1%) were susceptible, 5 (1.2%) 2021-01-01T00:00:00Z2021 Oct2026-05-29T06:02:57.998Z2024-11-05T20:26:02.788ZS-EPMC76147013461558110.5588/ijtld.21.0212